Congress punts on PBM reform efforts; Liver disease MASH is next target for obesity drugs in development

Taking stock of the drug industry, from the lab to the medicine chest

February 26, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

BRENDAN SMIALOWSKI/AFP/Getty Images STAT+ | Congress punts on PBM reform efforts Congress has abandoned its attempt to reform how PBMs operate in an upcoming package to fund the federal government, 11 sources said. By Rachel Cohrs and John Wilkerson STAT+ | Liver disease MASH is next target for obesity drugs in development Wegovy and Zepbound have spurred drug companies to study obesity treatments in the increasingly common liver disease MASH. By Elaine Chen STAT+ | Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH The drug, called survodutide and developed by Boehringer Ingelheim and Zealand Pharma, is also in Phase 3 trials for obesity. By Andrew Joseph Michael Ciaglo/Getty Images STAT+ | Amgen's rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado Colorado moves to cap the price of etanercept, an autoimmune drug sold by Amgen as Enbrel, in drive to lower prescription drug prices. By Rachel Cohrs and Ed Silverman STAT+ | Oregon suspends a portion of its drug transparency law found to be unconstitutional The ruling stems from the latest attempt by the pharmaceutical industry to push back against states trying to control drug spending. By Ed Silverman STAT+ | Annovis Bio delivers candor on its Parkinson's study, even if it doesn't inspire much confidence After a late change to the design of a Phase 3 study, Annovis Bio's clinical trial seems even less likely to succeed. By Adam Feuerstein Adobe STAT+ | San Diego biotech Neurocrine Biosciences joins PhRMA The company is the second to join PhRMA since the passage of the Inflation Reduction Act as the lobbying group rebuilds its membership By Rachel Cohrs STAT+ | Stump Pharmalot: An Ask Me Anything with Ed Silverman Ed Silverman answers questions exclusively for STAT+ Connect users on all things business of pharma. By STAT Staff

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser